Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5933287 | 0.74 | — | — | |
| SCHEMBL4565912 | 0.72 | PRSS1 (0.38) | TSHRCA1CA2CA9MEN1 | |
| SCHEMBL5932171 | 0.72 | THRB (0.42) | TSHRCA1CA2CA9MEN1 | |
| SCHEMBL5932453 | 0.72 | THRB (0.42) | TSHRCA1CA2CA9MEN1 | |
| SCHEMBL5932320 | 0.72 | THRB (0.42) | TSHRCA1CA2CA9MEN1 | |
| SCHEMBL6336308 | 0.72 | THRB (0.35) | TSHRCA1CA2CA9MEN1 | |
| SCHEMBL5932742 | 0.72 | THRB (0.42) | TSHRCA1CA2CA9MEN1 | |
| SCHEMBL5932707 | 0.72 | THRB (0.42) | TSHRCA1CA2CA9MEN1 | |
| SCHEMBL6331643 | 0.70 | THRB (0.40) | TSHRCA1CA2CA9MEN1 | |
| SCHEMBL10706187 | 0.70 | THRB (0.40) | TSHRCA1CA2CA9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1088098-B2 | FITNESS ASSAY AND METHODS FOR REDUCING RESISTANCE OF HIV TO THERAPY | US OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) | 2015-07-01 | — | — | EP | claimed |
| US-20140011815-A1 | FITNESS ASSAY AND ASSOCIATED METHODS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2014-01-09 | — | — | US | claimed |
| US-8597876-B2 | Method of treating HIV infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-12-03 | — | — | US | claimed |
| EP-2336134-A1 | Fitness assay and methods for reducing resistance of HIV to therapy | The United States of America, represented by the Secretary, Department of Health and Human Services (US) | 2011-06-22 | — | — | EP | claimed |
| EP-1088098-B1 | MEDICAMENT FOR TREATING HIV-INFECTED MAMMALS | US OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) | 2011-03-09 | — | — | EP | claimed |
| US-20090312318-A1 | THERAPEUTIC COMPOUNDS AND METHODS | GILEAD SCIENCES, INC. | 2009-12-17 | — | — | US | claimed |
| EP-2069356-A1 | BISFURANYL PROTEASE INHIBITORS | Gilead Sciences, Inc. (US) | 2009-06-17 | — | — | EP | claimed |
| US-20080085918-A1 | Fluorogenic; for measuring anti-HIV protease activity of inhibitor; drug resistance; bioavailability; can be used to predict the emergence of drug resistance for a particular replicating biological entity (e.g., a disease-causing cell) in the presence a drug (e.g., an inhibitor) | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY SECRETARY, DEPARTMEMT OF HEALTH AND (US) | 2008-04-10 | — | — | US | claimed |
| US-20080070910-A1 | Therapeutic compounds and methods | GILEAD SCIENCES, INC. | 2008-03-20 | — | — | US | claimed |
| WO-2008013834-A1 | BISFURANYL PROTEASE INHIBITORS | GILEAD SCIENCES, INC., (US) | 2008-01-31 | — | — | WO | claimed |
| US-20050158713-A1 | Fluorogenic; for measuring anti-HIV protease activity of inhibitor; drug resistance; bioavailability | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2005-07-21 | — | — | US | claimed |
| JP-2002518063-A | — | — | 2002-06-25 | — | — | JP | claimed |
| EP-1088098-A2 | FITNESS ASSAY AND ASSOCIATED METHODS | UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND SOCIAL SERVICES (US) | 2001-04-04 | — | — | EP | claimed |
| WO-1999067254-A2 | MULTI-DRUG RESISTANT RETROVIRAL PROTEASE INHIBITORS AND USE THEREOF | THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-29 | — | — | WO | claimed |
| WO-1999067417-A2 | FITNESS ASSAY AND ASSOCIATED METHODS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-29 | — | — | WO | claimed |
| US-9889115-B2 | Fitness assay and associated methods | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-02-13 | — | — | US | disclosed |
| EP-1088098-B2 | FITNESS ASSAY AND METHODS FOR REDUCING RESISTANCE OF HIV TO THERAPY | US OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) | 2015-07-01 | — | — | EP | disclosed |
| CN-1044672-A | COATING PROCESS AND COMPOSITION | COURTAULDS COATINGS LTD (GB) | 1990-08-15 | — | — | CN | disclosed |
| CN-1039435-A | Coating composition | COURTAULDS COATINGS LTD (GB) | 1990-02-07 | — | — | CN | disclosed |
| EP-0259172-A2 | Coating composition | COURTAULDS COATINGS (HOLDINGS) LIMITED (GB) | 1988-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011815-A1 | FITNESS ASSAY AND ASSOCIATED METHODS | CPS1, CTSS, TST | TSHR 3041/4885ALDH1A1 1735/4885FAAH 1034/4885 |
| US-20090312318-A1 | THERAPEUTIC COMPOUNDS AND METHODS | SERPINB1, ABCC1, SERPINB6 | TSHR 2054/4885ALDH1A1 1840/4885FAAH 2071/4885 |
| US-20080085918-A1 | Fluorogenic; for measuring anti-HIV protease activity of inhibitor; drug resistance; bioavailability; can be used to predict the emergence of drug resistance for a particular replicating biological entity (e.g., a disease-causing cell) in the presence a drug (e.g., an inhibitor) | CTSS, CTSE, FURIN | TSHR 3160/4885ALDH1A1 3823/4885FAAH 618/4885 |
| US-20080070910-A1 | Therapeutic compounds and methods | SERPINB1, ABCC1, SERPINB6 | TSHR 2054/4885ALDH1A1 1840/4885FAAH 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.